Wan Li, Zhang Lin, Fan Kai, Wang Jian-Jun
Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
Onco Targets Ther. 2017 Nov 28;10:5695-5702. doi: 10.2147/OTT.S149314. eCollection 2017.
We have previously shown that the long noncoding RNA prostate cancer-associated transcript 6 (PCAT6) promoted the proliferation and invasion of lung adenocarcinoma (LUAD) cells. In this study, the diagnostic significance of tissue and serum PCAT6 was evaluated in non-small cell lung cancer (NSCLC).
Tissue expression of PCAT6 was systematically evaluated in five Gene Expression Omnibus datasets (GSE19804, GSE18842, GSE30219, GSE19188, and GSE27262). Circulating and tissue expressions of PCAT6 were detected by quantitative reverse-transcriptase polymerase chain reaction in NSCLC patients from Union Hospital.
PCAT6 was significantly increased in lung cancer tissues and could be used to distinguish LUAD from adjacent normal tissues with an area under the receiver operating characteristic curve (AUC) of 0.9210 (<0.0001; sensitivity, 98.82%; specificity, 78.57%) in GSE30219, 0.9333 (<0.0001; sensitivity, 86.67%; specificity, 90.77%) in GSE19188, 0.9584 (<0.0001; sensitivity, 92.00%; specificity, 96.00%) in GSE27262, and 0.9574 (<0.0001; sensitivity, 95.89%; specificity, 87.67%) in patients from Union Hospital. As for lung squamous cell carcinoma (LUSC), the AUC of PCAT6 was 0.9567 (<0.0001; sensitivity, 100%; specificity, 85.71%) in GSE30219, 0.9795 (<0.0001; sensitivity, 96.30%; specificity, 92.31%) in GSE19188, and 0.9942 (<0.0001; sensitivity, 100%; specificity, 98.04%) in patients from Union Hospital. We further noticed that the plasma levels of PCAT6 were significantly increased in 73 LUAD and 51 LUSC patients compared with 39 healthy controls (<0.0001). The AUC of circulating PCAT6 was 0.9213 (<0.0001; sensitivity, 87.67%; specificity, 97.44%) in LUAD and 0.9583 (<0.0001; sensitivity, 94.12%; specificity, 100%) in LUSC.
Together with our previous findings, our results suggest that PCAT6 could be used as a potential diagnostic and prognostic biomarker in NSCLC.
我们之前已经表明，长链非编码RNA前列腺癌相关转录本6（PCAT6）促进肺腺癌（LUAD）细胞的增殖和侵袭。在本研究中，评估了组织和血清PCAT6在非小细胞肺癌（NSCLC）中的诊断意义。
在五个基因表达综合数据库（GSE19804、GSE18842、GSE30219、GSE19188和GSE27262）中系统评估了PCAT6的组织表达。通过定量逆转录聚合酶链反应检测了华中科技大学同济医学院附属协和医院NSCLC患者的循环和组织中PCAT6的表达。
PCAT6在肺癌组织中显著升高，在GSE30219中，其受试者工作特征曲线下面积（AUC）为0.9210（<0.0…显示全部
我们之前已经表明，长链非编码RNA前列腺癌相关转录本6（PCAT6）促进肺腺癌（LUAD）细胞的增殖和侵袭。在本研究中，评估了组织和血清PCAT6在非小细胞肺癌（NSCLC）中的诊断意义。
在五个基因表达综合数据库（GSE19804、GSE18842、GSE30219、GSE19188和GSE27262）中系统评估了PCAT6的组织表达。通过定量逆转录聚合酶链反应检测了华中科技大学同济医学院附属协和医院NSCLC患者的循环和组织中PCAT6的表达。
PCAT6在肺癌组织中显著升高，在GSE30219中，其受试者工作特征曲线下面积（AUC）为0.9210（<0.0001；灵敏度，98.82%；特异性，78.57%），在GSE19188中为0.9333（<0.0001；灵敏度，86.67%；特异性，90.77%），在GSE27262中为0.9584（<0.0001；灵敏度，92.00%；特异性，96.00%），在协和医院患者中为0.9574（<0.0001；灵敏度，95.89%；特异性，87.67%）。至于肺鳞状细胞癌（LUSC），在GSE30219中PCAT6的AUC为0.9567（<0.0001；灵敏度，100%；特异性，85.71%），在GSE19188中为0.9795（<0.0001；灵敏度，96.30%；特异性，92.31%），在协和医院患者中为0.9942（<0.0001；灵敏度，100%；特异性，98.04%）。我们进一步注意到，与39名健康对照相比，73例LUAD和51例LUSC患者血浆中PCAT6水平显著升高（<0.0001）。循环PCAT6在LUAD中的AUC为0.9213（<0.0001；灵敏度，87.67%；特异性，97.44%），在LUSC中为0.9583（<0.0001；灵敏度，94.12%；特异性，100%）。
结合我们之前的研究结果，我们的结果表明PCAT6可作为NSCLC潜在的诊断和预后生物标志物。
